Business
Terns Pharmaceuticals Announces Publication of TERN-701 Trial-in-Progress Abstract for the 2023 ASCO Annual Meeting
- Enrollment progress update from ongoing China Phase 1 trial of TERN-701 (allosteric BCR-ABL) to be presented at ASCO 2023 - China Phase 1 trial completed
About this update from Terns Pharmaceuticals, Inc.
[{"type":"text","content":"- Enrollment progress update from ongoing China Phase 1 trial of TERN-701 (allosteric BCR-ABL) to be presented at ASCO 2023 - China Phase 1 trial completed enrollment of Cohort 5 in the Dose Escalation phase FOSTER CITY, Calif., May 25, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, non-alcoholic steatohepatitis (NASH) and obesity, today announced that the TERN-701 (HS-10382) trial-in-progress (TiP) abstract is now available on the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting website. The ASCO Annual Meeting will be held in person at McCormick Place in Chicago, Illinois, and online from June 2 - 6, 2023. The TiP abstract details that patient enrollment reached Cohort 3 of the Dose Escalation phase as of February 2023, with seven participating study sites in China. The TiP poster highlights completion of enrollment of Cohort 5 as of April 2023. Following are details of the upcoming TERN-701 TiP poster presentation: Abstract Title: A Phase 1, multicenter, open-label, dose-escalation and dose-expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of HS-10382 (TERN-701) in patients (pts) with chronic myeloid leukemia (CML)Abstract # TPS7081Presenter: Jiawei Wei, MD, PhD, Hansoh Pharmaceuticals Group Co. LtdPoster Session: Hematologic Malignancies – Leukemia, Myelodysplastic Syndromes, and AllotransplantDate/Time: Monday, June 5, 2023 from 8:00 AM-11:00 AM CT “We are encouraged by the speed at which our partner Hansoh has progressed the dose escalation part of the Phase 1 trial in China. This reaffirms our hope that we could potentially see data accepted for presentation later this year,” said Sen Sundaram, chief executive officer at Terns. “In addition to our planned virtual CML R&D event in July, we also look forward to the initiation of our Phase 1 U.S. clinical trial of TERN-701 in the second half of this year.” The full abstract of the TERN-701 poster is available online at: ASCO.org/abstracts. About Terns PharmaceuticalsTerns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseas...